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Summary Serum levels of a-lactalbumin were assayed using a monoclonal antibody specific for this breast
specific molecule. Elevated levels were found in 87% (48/55) of sera from women in the third trimester of
pregnancy (29.1 ± 7.4 ng ml-'), from 64% (62/97) of patients with breast cancer (23.4 ± 5.6 ngml-'), and
from 70% (56/80) of patients with gynaecological cancers (19.4 ± 6.7 ngml-'). These x-lactalbumin levels were
significantly higher (P<0.001) than those for men and non-pregnant women (11.0 ± 2.3 ngml-') and for
patients with other, non-gynaecological cancers (13.4 ± 3.6 ng ml-'). The ax-lactalbumin levels were higher in
patients with stage IV breast cancer than those with stage I-III breast cancer. The overall sensitivity and
specificity of the radioimmunoassay were 72% and 75% respectively. These findings suggest that the assess-
ment of serum levels of a-lactalbumin may be useful as a marker for monitoring breast cancer.
Human a-lactalbumin, comprising 123 amino acid residues
(Findlay & Brew 1972), is a modifier protein of galactosyl
transferase, an enzyme involved in lactose production. Since
the human ax-lactalbumin is breast restricted, it is uniquely
placed as a breast marker. Indeed, experiments with rodent
mammary tumours have shown that this is the case (Schultz
& Ebner, 1977a; Zamierowski & Ebner, 1980). However,
previous attempts to exploit human a-lactalbumin as a
marker for human breast cancer using polyclonal rabbit
antisera have been unsuccessful (Kleinberg, 1975; Schultz &
Ebner, 1977b; Woods & Heath, 1977). This is probably due
to the presence of 'natural' antibodies to bovine a-
lactalbumin which cross react with human x-lactalbumin
(Woods & Heath, 1978). These natural antibodies, which
have a higher affinity for bovine x-lactalbumin than for
human a-lactalbumin (Zangerle & Franchimont, 1985), may
have arisen through dietary exposure to cow's milk.
To overcome these problems, we have produced a murine
monoclonal antibody which binds specifically to human x-
lactalbumin and which does not cross-react with bovine a-
lactalbumin (Thean & Toh, 1989a,b). The present report
describes the application of the monoclonal antibody in a
radioimmunoassay carried out in the presence of bovine
a-lactalbumin, to release human a-lactalbumin pre-bound to
the 'natural' antibodies.
Materials and methods
Human a-lactalbumin
The human a-lactalbumin (Calbiochem, USA) used for the
production and characterization of the monoclonal antibody
was also used as a standard for the RIA. The purity of the
protein was confirmed by two-dimensional (IEF/PAGE) gel
electrophoresis (O'Farrell, 1975).
Monoclonal antibodies
The murine monoclonal antibody ET-1 binds specifically to
human a-lactalbumin and does not cross-react with bovine
a-lactalbumin or bind to human albumin, casein or other
milk proteins as assessed by ELISA, Western blotting and
immunoprecipitation. Furthermore, the specificity of the
antibody for human x-lactalbumin was confirmed by specific
inhibition of binding by human x-lactalbumin but not by
bovine a-lactalbumin, human albumin or casein (Thean &
Toh, 1989a,b).
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Patients
Sera were collected from patients with benign and malignant
neoplasms attending the Alfred Hospital, Melbourne, from
healthy blood donors (Red Cross Blood Bank, Melbourne)
and from women in the third trimester of pregancy (Royal
Women's Hospital, Melbourne). All sera were coded and
stored at -20'C. Clinical parameters, such as extent of
disease were provided by staff clinicians. Screening was per-
formed 'blind', i.e without prior knowledge of the origin of
the samples to prevent bias in the interpretation of the
results.
Assay andstatistical analysis
The solid phase, competitive RIA for human a-lactalbumin
was performed as follows. Five micrograms of rabbit anti-
mouse Ig (RAM Ig, DAKO Denmark) were incubated with
1 ml of a 10% (w/v) suspension of Cowan 1 strain Staph.
aureus for 30 min at 4°C. The rabbit anti-mouse-Staph.
aureus complex (RAMSA) was washed 3 times in 50 mM
Tris/HCI, 0.6M NaCl, 0.5% Triton X 100, pH 8.3 and
resuspended to a 10% (w/v) bacterial suspension. One ml
(500 ng) of the monoclonal antibody specific for human a-
lactalbumin (ET-1) was bound to one ml of RAMSA by
incubation for 6 h at 4'C to produce RAMSET.
Radioiodinated human x-lactalbumin tracer (8 x I05c.p.m.
per 2 ml PBS, 0.2% BSA, specific activity 2,000 Ci mmol 1)
was added to the 2 ml of RAMSET and incubated overnight
at 4'C with constant mixing.
Human sera was diluted 1/10 in PBS, 0.2% BSA contain-
ing 0.2% bovine a-lactalbumin and incubated overnight at
4'C to block natural antibody activity and to release bound
human a-lactalbumin. The blocked sera and human a-
lactalbumin standards (100IL) were incubated with the tracer
bound RAMSET (100p1) in duplicate for 48 h at 4°C with
constant mixing.
The coefficient of extinction of the human ax-lactalbumin
standards was E0.1% 280= 1.8. The bound counts were deter-
mined in the pellet after centrifugation at 10,000 g for 5 min.
The amount of human a-lactalbumin in the serum samples
were extrapolated from a standard curve plotted as B/
Bo x 100 versus log human a-lactalbumin concentration
where B is the bound counts and Bo is the maximum counts
bound. Grouped data were evaluated statistically using the
unpaired Student's t test.
Results
Figure 1 shows the purity of the human a-lactalbumin
analysed by two-dimensional gel electrophoresis and stained
with Coomassie Blue; the protein is seen as a single acidic
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Figure 1 Two-dimensional gel electrophoresis showing the purity
of human a-lactalbumin. The location of aE-lactalbumin (mol. wt
14.5 kDa) on the gel is bracketed ([ ]). The spots at 92 kDa
(phosphoylase B), 50 kDa (IgG heavy chain) and 25 kDa (IgG
light chain) were included as markers.
spot of 14.5 kDa. Figure 2 is a typical standard curve for the
human a-lactalbumin RIA. Intra- and inter-assay variations
between several curves were compared and found to be
insignificant, showing the reproducibility of the assay. The
presence of bovine x-lactalbumin did not affect the standard
curve significantly especially in the useful range.from 10 to
30 ngml.-'
The mean level of ax-lactalbumin found in 110 normal
individuals (male and female) was 11 + 2.3 ng ml-' (Table 1).
Although there was variation between individuals, no statis-
tically significant difference in circulating a-lactalbumin levels
(P<0.21) was observed in age and sex matched controls. The
cut off point distinguishing normal from elevated levels was
arbitrarily set at 18 ngml-' (mean + 3 s.d. = 17.9 ng ml').
Using this cut off and taking the levels for the third trimester
of pregnancy as true positive and those of normal controls as
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true negative, the sensitivity of the assay was 72% and the
specificity 75%.
Levels of human a-lactalbumin were elevated in sera from
patients with breast cancer (mean = 23.4 ± 5.6 ng ml-')
(Table II). The highest levels were from patients with stage
IV breast cancer. Eighty-five per cent of these patients have
levels higher than the cut off and were matched only by those
women in the last trimester of pregnancy. The elevated levels
from patients with stage I-III breast cancer, were of the
same order of magnitude as those from patients with
gynaecological cancer. These levels were significantly higher
(P<0.001) than those from controls, from women with
benign breast tumours, and from patients with non-
gynaecological cancers (Figure 3).
Discussion
The measurement of human serum a-lactalbumin is often
hampered by the presence of endogenous cross reacting
antibodies to bovine a-lactalbumin (Woods & Heath, 1978;
Zangerle & Franchimont, 1985). The present study is the first
report of the application of a monoclonal antibody specific
for human a-lactalbumin for a radioimmunoassay which has
been developed to overcome this interference by the
endogenous antibodies.
The levels of human a-lactalbumin in the sera of normal
male and pregnant and non-pregnant females were initially
assessed (Table I). All these sera showed detectable levels of
a-lactalbumin. The reason for the occurrence of a-
lactalbumin in normal male sera in not known. However,
because the range ofa-lactalbumin levels in the sera of males
and non-pregnant females is narrow, they can be distin-
guished from the sera of individuals with elevated levels. The
levels of human x-lactalbumin were approximately three
times higher in pregnant females compared to males and
non-pregnant females. The elevation of human a-lactalbumin
levels in pregnancy is an expected finding and is consistent
with previous reports (e.g. Martin et al., 1980). These
differences in the values obtained for pregnant females versus
males and non-pregnant females validate the use of the assay
as a quantitative test for circulating levels of human a-
lactalbumin. For the purposes of the present study, the levels
in males and non-pregnant females were taken as the baseline
normal, negative controls and the levels in pregnant females
as the positive controls.
Using the value of 18 ng ml-' (equivalent to the mean + 3
standard deviations of the negative controls) as the upper
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Figure 2 Standard curve for human ca-lactalbumin radioim-
munoassay. * *, 100 ng bovine a-lactalbumin per tube;
O 0, without bovine a-lactalbumin.
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Figure 3 Circulating levels of human a-lactalbumin. Means (U)
± 2 standard deviations (bars) shown for each group. The arbit-
rary cut-off level of 18 ngml1' was derived from the mean plus 3
standard deviations of the total male and female control groups.
Gynaecological cancer comprised cancer of the ovary (n = 70),
cervix (n = 5) and endometrium (n = 5). Miscellaneous cancers
comprised cancer of the stomach (n = 3), leukaemia (n = 8), lung
(n = 5), lymphomas (n = 7) and melanomas (n = 2).
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Table I a-Lactalbumin levels in non-cancer sera
Number Serum oa-lactalbunin
Samples PostivelTotal (%) mean (ngmlh') (s.d.)
Third trimester
pregnancy sera 48/55 (87.3) 29.11 (7.4)
Benign breast
tumour sera 3/22 (13.6) 13.33 (4.8)
Normal male sera 0/55 (0) 11.31 (2.4)
Normal female sera 0/55 (0) 10.75 (2.2)
Normal sera
(male and female) 11.03 (2.3)
Cut off level of human m-lactalbumin = 18 ng ml-'
limit of normal values, the results of the assays for the sera
of patients with benign and malignant breast lesions showed
that circulating x-lactalbumin levels were elevated in the sera
of over 64% of patients with breast cancer. These results
were significantly higher (P<0.001) than the values for a-
lactalbumin found in the sera of women with benign breast
tumours and in the controls (males and non-pregnant
females). Significantly, the levels of az-lactalbumin in the sera
of patients with benign breast lesions were not elevated. The
elevated levels in breast cancer were due entirely to the high
levels in patients with stage IV breast cancer with 85% of
patients having raised levels (Tables I and II and Figure 3).
The elevated levels in stage IV breast cancer were of the same
order of magnitude as those observed for pregnant females.
In the sera of patients with stage I, II and III breast cancer,
the mean a-lactalbumin levels were also elevated, but only
less than twice the mean of the normal level and the
differences were not statistically significant (P<0.2). The
levels of a-lactalbumin for patients with other non-breast
cancers were not elevated (Table II and Figure 3). However,
the levels in patients with gynaecological cancers were
elevated.
It must be emphasised that the results obtained by this
RIA may not represent the true serum x-lactalbumin concen-
trations. Although the human x-lactalbumin used in the stan-
dard curve was purified to homogeneity, there is the question
of stability, heterogeneity of the protein in different popula-
tions and salt content which may affect the specific activity of
the purified protein (Bangham & Cotes, 1971). Hence, the
concentration of human a-lactalbumin reported here cannot
Table II a-Lactalbumin levels in cancer sera
Number Serum ot-lactalbumin
Cancer PostivelTotal (%) mean (ngml') (s.d.)
Breast
Stage I 8/20 (40.0) 16.18 (3.8)
Stage II 11/18 (61.1) 18.29 (3.4)
Stage III 15/27 (55.5) 17.73 (3.9)
Stage IV 28/32 (87.5) 29.35 (7.2)
Gynaecologicala 56/80 (70.0) 19.14 (6.7)
Miscellaneousb 3/25 (12.0) 13.43 (3.6)
Cut offlevel ofhuman a-lactalbumin = 18 ng ml'-'. aGynaecological
cancers include cancer of the ovary (51 positives), cervix (3 positives)
and endometrium (2 positives). bMiscellaneous cancers include
melanoma, lymphoma (2 positives), leukaemia, carcinoma of the
stomach, colon and lung (1 positive).
be accurately compared with published results using other
standards which will have different effective constituents.
Since the molecule is restricted strictly to breast tissue, the
elevated serum levels found in patients with gynaecological
cancers is an unexpected result. This appears to be a com-
mon occurrence among assays for other milk related
antigens. RIAs of HMFG2 (Burchell et al., 1984), DF3
antigen (Hayes et al., 1985) and MAM6 antigen (Hilkens et
al., 1984) have also shown high levels of the respective
antigens in ovarian carcinoma. It may be that gynaecological
tumours to produce and secrete milk proteins (Ray et al.,
1986). However, the distinction between breast and
gynaecological cancers is not a diagnostic problem.
The RIA for human a-lactalbumin at its present level of
sensitivity is not suitable for widespread diagnostic screening,
since the antigen is not elevated significantly in the sera of
patients with early breast cancer. Before the value of the
human a-lactalbumin assay as a breast cancer monitoring test
can be established, more studies on sera from patients with
breast and non-breast cancers need to be carried out. Fur-
thermore, longitudinal and comparative studies with other
markers should also be helpful in defining the predictive
value of human a-lactalbumin levels for breast cancer, and in
assessing whether these levels will be useful in monitoring
breast cancer before and after treatment.
We thank Dr J. Tjandra and Dr M. Cauchi for the serum samples
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